Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.
   PubMed Web of Science ®Google Scholar
• Kurman RJ, Shih I. The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded. Am J Pathol. 2016;186:733–747.
   PubMed Web of Science ®Google Scholar
• Vaughan S, Coward JI, Bast HRC, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011;11:719–725.
   PubMed Web of Science ®Google Scholar
• Leone Roberti Maggiore U, Valenzano Menada M, Venturini PL, et al. Sorafenib for ovarian cancer. Expert Opin Investig Drugs. 2013;22:1049–1062.
   PubMed Web of Science ®Google Scholar
• Leone Roberti Maggiore U, Valenzano Menada M, Venturini PL, et al. The potential of sunitinib as a therapy in ovarian cancer. Expert Opin Investig Drugs. 2013;22:1671–1686.
   PubMed Web of Science ®Google Scholar
• Marchetti C, Ledermann JA, Benedetti Panici P. An overview of early investigational therapies for chemoresistant ovarian cancer. Expert Opin Investig Drugs. 2015;24:1163–1183.
   PubMed Web of Science ®Google Scholar
• Bergamini A, Leone Roberti Maggiore U, Ferrero S, et al. Investigational therapies currently in phase II clinical trials for the treatment of pelvic serous carcinomas. Expert Opin Investig Drugs. 2015;24:345–362.
   PubMed Web of Science ®Google Scholar
• Vergote I, Marth C, Coleman RL. Role of the folate receptor in ovarian cancer treatment: evidence, mechanism and clinical implication. Cancer Metastasis Rev. 2015;34:41–52.
   PubMed Web of Science ®Google Scholar
• Zhao R, Diop-Bove N, Visentin M, et al. Mechanisms of membrane trasnsport of folate into cells and across epithelia. Annu Rev Nutr. 2011;31:177–201.
   PubMed Web of Science ®Google Scholar
• Elnakat H, Ratnam M. Role of folate receptor genes in reproduction and related cancers. Front Biosci. 2006;11:506–519.
   PubMed Web of Science ®Google Scholar
• Ross JF, Chauduri PK, Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and Clinical Implications. Cancer. 1994;73:2432–2443.
   PubMed Web of Science ®Google Scholar
• Despierre E, Lambrechts S, Leunen K, et al. Folate receptor alpha (FRA) expression remains unchanged in epithelial ovarian and endometrial cancer after chemotherapy. Gynecol Oncol. 2013;130:192–199.
   PubMed Web of Science ®Google Scholar
• Merkert S, Lassmann S, Gabriel B, et al. Alpha-folate receptor expression in epithelial ovarian carcinoma and non-neoplastic ovarian tissue. Anticancer Res. 2008;28:3567–3572.
   PubMed Web of Science ®Google Scholar
• Chen YL, Chang MC, Huang CY, et al. Serous ovarian carcinoma patients with high alpha folate receptor had reducing survival and cytotoxic chemo-response. Mol Oncol. 2012;6:360–369.
   PubMed Web of Science ®Google Scholar
• Ledermann JA, Canevari S, Thigpen T. Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments. Ann Oncol. 2015;26:2034–2043.
   PubMed Web of Science ®Google Scholar
• Bremer RE, Scoggin TS, Somers EB, et al. Interobserver agreement and assay reproducibility of folate receptor alpha expression in lung adenocarcinoma: a prognostic marker and potential therapeutic target. Arch Pathol Lab Med. 2013;137:1747–1752.
   PubMed Web of Science ®Google Scholar
• Toffoli G, Cernigoi C, Russo A, et al. Overexpression of folate binding protein in ovarian cancer. Int J Cancer. 1997;74:193–198.
   PubMed Web of Science ®Google Scholar
• Cardinale D, Guaitoli G, Tondi D, et al. Protein-protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase. Proc Natl Acad Sci U S A. 2011;108:E542–E549.
   PubMed Web of Science ®Google Scholar
• Morris R, Joyrich RN, Naumann RW, et al. Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-etarfolatide). Ann Oncol. 2014;25:852–858.
   PubMed Web of Science ®Google Scholar
• Naumann RW, Coleman RL, Burger RA, et al. PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2013;31:4400–4406.
   PubMed Web of Science ®Google Scholar
• Vergote I, Leamon CP. Vintafolide: a novel targeted therapy for the treatment of folate receptor expressing tumors. Ther Adv Med Oncol. 2015;7:206–218.
   PubMed Web of Science ®Google Scholar
• Wen Y, Graybill WS, Previs RA, et al. Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer. Clin Cancer Res. 2015;21(2):448–459.
   PubMed Web of Science ®Google Scholar
• Bottero S, Tomassetti A, Canevari S, et al. Gene transfection and expression of the ovarian carcinoma marker folate binding protein on NIH/3T3 cells increases cell growth in vitro and in vivo. Cancer Res. 1993;53:5791–5796.
   PubMed Web of Science ®Google Scholar
• Miotti S, Bagnoli M, Tomassett A, et al. Interaction of folate receptor with signaling molecules lyn and G(alpha)(i-3) in detergent resistant complexes from the ovary carcinoma cell line IGROV1. J Cell Sci. 2000;113:349–357.
   PubMed Web of Science ®Google Scholar
• Jelovac D, Armstrong D. Role of farletuzumab in in epithelial ovarian carcinoma. Curr Pharm Des. 2012;18:3812–3815.
   PubMed Web of Science ®Google Scholar
• Figini M, Ferri R, Mezzanzanica D, et al. Reversion of transformed phenotype in ovarian cancer cells by intracellular expression of anti folate receptor antibodies. Gene Ther. 2003;10:1018–1025.
   PubMed Web of Science ®Google Scholar
• Kalli KR, Oberg AL, Keeney GL, et al. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol. 2008;108:619–626.
   PubMed Web of Science ®Google Scholar
• Farrell C, Schweizer C, Wustner J, et al. Population pharmacokinetics of farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer. Cancer Chemother Pharmacol. 2012;70:727–734.
   PubMed Web of Science ®Google Scholar
• Ebel W, Routhier EL, Foley B, et al. Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun. 2007;7:6.
   PubMedGoogle Scholar
• Kim KH, Jelovac D, Armstrong DK, et al. Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer. Gynecol Oncol. 2016;140:210–214.
   PubMed Web of Science ®Google Scholar
• Armstrong DK, White AJ, Weil SC, et al. Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer. Gynecol Oncol. 2013;129:452–458.
   PubMed Web of Science ®Google Scholar
• Vergote I, Armstrong D, Scambia G, et al. A randomized, double-blind, placebo-controlled, phase iii study to assess efficacy and safety of weekly farletuzumab in combination with carboplatin and taxane in patients with ovarian cancer in first platinum-sensitive relapse. J Clin Oncol. 2016;34:2271–2278.
   PubMed Web of Science ®Google Scholar
• Coney LR, Tomassetti A, Carayannopoulos L, et al. Cloning of a tumor- associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein. Cancer Res. 1991;51:6125–6132.
   PubMed Web of Science ®Google Scholar
• Coney LR, Mezzanzanica D, Sanborn D, et al. Chimeric murine-human antibodies directed against folate binding receptor are efficient mediators of ovarian carcinoma cell killing. Cancer Res. 1994;54:2448–2455.
   PubMed Web of Science ®Google Scholar
• Gould H, Mackay G, Karagiannis S, et al. Comparison of IgE and IgG antibody-dependent cytotoxicity in vitro and in SCID mouse xenograft model of ovarian carcinoma. Eur J Immunol. 1999;29:3527–3537.
   PubMed Web of Science ®Google Scholar
• Karagiannis SN, Wang Q, East N, et al. Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells. Eur J Immunol. 2003;33:1030–1040.
   PubMed Web of Science ®Google Scholar
• Karagiannis SN, Josephs DH, Karagiannis P, et al. Recombinant IgE antibodies for passive immunotherapy of solid tumors: from concept towards clinical application. Cancer Immunol Immunother. 2012;61:1547–1564.
   PubMed Web of Science ®Google Scholar
• Josephs DH, Bax HJ, Lentfer H, et al. Potential for monocyte recruitment by IgE immunotherapy for cancer in a rat model of tumour metastasis. Lancet. 2015;385(Suppl 1):S53.
   PubMedGoogle Scholar
• Ab O, Whiteman KR, Bartle LM, et al. IMGN853, a Folate Receptor-α (FRα)-ZARGETING antibody-drug conjugate, exhibits potent targeted antitumor activity against FRα-expressing tumors. Mol Cancer Ther. 2015;14:1605–1613.
   PubMed Web of Science ®Google Scholar
• Kovtun YV, Audette CA, Ye Y, et al. Antibody drug conjugate designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res. 2006;66:3214–3221.
   PubMed Web of Science ®Google Scholar
• Moore K, Martin LP, Matulonis UA, et al. IMGN853 (mirvetuximab soravtansine) a folate receptor alpha (FRα) targeting antibody-drug conjugate (ADC): single-agent activity in platinum-resistant epithelial ovarian cancer (EOC) patients (pts). J Clin Oncol. 2016;34(suppl; abstr 5567).
   Google Scholar
• Basal E, Eghbali-Fatourechi GZ, Kalli KR, et al. Functional folate receptor alpha is elevated in the blood of ovarian cancer patients. PLoS One. 2009;4:e6292.
   PubMed Web of Science ®Google Scholar
• Hernando JJ, Park TW, Fischer HP, et al. Vaccination with dendritic cells transfected with mRNA-encoded folate-receptor-alpha for relapsed metastatic ovarian cancer. Lancet Oncol. 2007;8:451–454.
   PubMed Web of Science ®Google Scholar
• Murtaza Kasi P, Kalli K, Stephen Block M, et al. A phase I trial of the safety and immunogenicity of a multi-epitope folate receptor alpha peptide vaccine used in combination with cyclophosphamide in subjects previously treated for breast or ovarian cancer. J Clin Oncol. 2015;33(suppl; abstr e14028).
   Google Scholar
• Canevari S, Stoter G, Arienti F, et al. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst. 1995;87:1463–1469.
   PubMed Web of Science ®Google Scholar
• Miotti S, Negri DR, Valota O, et al. Level of anti-mouse-antibody response induced by bi-specific monoclonal antibody OC/TR in ovarian-carcinoma patients is associated with longer survival. Int J Cancer. 1999;84:62–68.
   PubMed Web of Science ®Google Scholar
• Kershaw MH, Westwood JA, Parker LL, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res. 2006;12:6106–6115.
   PubMed Web of Science ®Google Scholar
• Schutsky K, Song DG, Lynn R, et al. Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor. Oncotarget. 2015;6:28911–28928.
   PubMed Web of Science ®Google Scholar
• Song DG, Ye Q, Carpenito C, et al. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res. 2011;71:4617–4627.
   PubMed Web of Science ®Google Scholar
• Cheung A, Bax HJ, Josephs DH, et al. Targeting folate receptor alpha for cancer treatment. Oncotarget. 2016 [Epub ahead of print]. DOI:10.18632/oncotarget.9651
   Web of Science ®Google Scholar
• Chmielewski M, Kopecky C, Hombach AA, et al. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 2011;71:5697–5706.
   PubMed Web of Science ®Google Scholar
• Gargett T, Brown MP. The inducible caspase-9 suicide gene system as a “safety switch” to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Front Pharmacol. 2014;5:235.
   PubMed Web of Science ®Google Scholar